Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Genetic Technologies Ltd
NASDAQ:GENE

Watchlist Manager
Genetic Technologies Ltd Logo
Genetic Technologies Ltd
NASDAQ:GENE
Watchlist
Price: 0.765 USD Market Closed
Market Cap: $2.5m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

Revenue
+
3Y
+72%
5Y
+48 664%
10Y
-2%
Operating Income
+
3Y
+9%
5Y
-13%
10Y
+32%
Net Income
+
3Y
-29%
5Y
-63%
10Y
+2%

Earnings Waterfall
Genetic Technologies Ltd

Income Statement
Genetic Technologies Ltd

Rotate your device to view
Income Statement
Currency: AUD
Jun-2003 Dec-2003 Jun-2004 Dec-2004 Jun-2005 Dec-2005 Jun-2006 Dec-2006 Jun-2007 Dec-2007 Jun-2008 Dec-2008 Jun-2009 Dec-2009 Jun-2010 Dec-2010 Jun-2011 Dec-2011 Jun-2012 Dec-2012 Jun-2013 Dec-2013 Jun-2014 Dec-2014 Jun-2015 Dec-2015 Jun-2016 Dec-2016 Jun-2017 Dec-2017 Jun-2018 Dec-2018 Jun-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024 Dec-2024
Revenue
Interest Expense
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Revenue
9
N/A
7
-28%
5
-19%
10
+87%
11
+7%
9
-13%
11
+14%
8
-26%
15
+92%
20
+33%
16
-22%
10
-40%
12
+27%
8
-32%
10
+20%
9
-5%
5
-51%
4
-10%
4
-10%
4
-4%
3
-5%
4
+8%
5
+25%
4
-17%
2
-47%
1
-43%
1
-28%
1
-3%
1
-35%
0
-52%
0
-23%
0
-42%
0
-77%
0
-70%
0
+30%
0
+160%
0
+369%
2
+1 687%
7
+215%
9
+31%
9
-2%
8
-2%
8
-10%
4
-52%
Gross Profit
Cost of Revenue
(2)
(1)
(3)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(3)
(3)
(6)
(2)
(7)
(2)
(4)
(2)
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(1)
(3)
(4)
(4)
(4)
(4)
(2)
Gross Profit
7
N/A
6
-26%
3
-49%
8
+193%
9
+11%
7
-19%
9
+17%
6
-33%
13
+127%
19
+41%
14
-23%
7
-54%
9
+40%
5
-51%
7
+61%
2
-76%
3
+48%
(3)
N/A
2
N/A
(1)
N/A
1
N/A
0
-72%
3
+583%
1
-52%
1
-15%
0
-61%
0
-81%
(0)
N/A
0
N/A
(0)
N/A
(0)
-8%
(0)
-5%
(0)
-116%
(0)
-53%
(0)
+76%
(0)
+30%
(0)
+22%
1
N/A
4
+289%
5
+30%
4
-12%
5
+5%
4
-14%
2
-56%
Operating Income
Operating Expenses
(10)
(12)
(12)
(15)
(19)
(19)
(16)
(16)
(16)
(16)
(17)
(14)
(17)
(14)
(15)
1
(2)
(4)
(13)
(10)
(11)
(11)
(13)
(12)
(11)
(9)
(9)
(8)
(8)
(7)
(6)
(6)
(6)
(6)
(6)
(8)
(8)
(9)
(11)
(14)
(15)
(14)
(15)
(9)
Selling, General & Administrative
(4)
(6)
(5)
(8)
(7)
(10)
(8)
(8)
(8)
(10)
(9)
(11)
(9)
(10)
(2)
(7)
(7)
(11)
(10)
(11)
(10)
(10)
(9)
(9)
(9)
(8)
(7)
(6)
(6)
(5)
(4)
(4)
(4)
(4)
(4)
(3)
(6)
(4)
(12)
(15)
(11)
(11)
(12)
(7)
Research & Development
(1)
(0)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(0)
(3)
(4)
(6)
(4)
(4)
(3)
(3)
(3)
(3)
(3)
(2)
(3)
(3)
(2)
(2)
(2)
(3)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
0
Depreciation & Amortization
(3)
(4)
(4)
(4)
(4)
(5)
(5)
(5)
(5)
(5)
(5)
(4)
(4)
(4)
(4)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
0
(0)
0
(1)
(0)
(1)
(1)
(1)
(0)
Other Operating Expenses
(3)
(2)
(3)
(2)
(6)
(4)
(3)
(1)
(2)
(1)
(2)
3
(3)
1
(8)
13
10
13
1
5
3
2
0
1
1
1
1
0
0
0
0
1
1
1
(1)
(3)
(0)
(3)
2
2
(2)
(2)
(2)
(1)
Operating Income
(3)
N/A
(6)
-142%
(10)
-52%
(7)
+28%
(9)
-38%
(12)
-26%
(8)
+35%
(10)
-29%
(3)
+74%
2
N/A
(3)
N/A
(7)
-146%
(8)
-11%
(8)
-13%
(7)
+12%
5
N/A
1
-78%
(7)
N/A
(11)
-58%
(11)
+2%
(9)
+16%
(11)
-15%
(10)
+7%
(10)
-5%
(10)
+7%
(8)
+12%
(9)
-1%
(8)
+4%
(8)
+5%
(8)
+3%
(6)
+19%
(6)
+7%
(6)
-5%
(6)
-3%
(7)
-6%
(8)
-19%
(8)
+1%
(8)
+0%
(8)
+1%
(9)
-15%
(10)
-17%
(10)
+4%
(11)
-9%
(7)
+34%
Pre-Tax Income
Interest Income Expense
(1)
(1)
(1)
(0)
(1)
0
(0)
(0)
(0)
(0)
(0)
1
(0)
0
(0)
(0)
0
0
1
0
(0)
(1)
(1)
(1)
(1)
0
0
0
(0)
(0)
0
0
0
0
(0)
(0)
0
0
0
0
0
0
(0)
(0)
Non-Reccuring Items
(1)
0
0
0
0
0
(0)
0
(1)
(1)
(2)
(2)
(0)
(0)
(2)
(2)
(0)
(0)
5
5
0
1
1
2
1
(0)
0
(0)
(0)
0
1
0
(1)
0
0
1
0
0
0
(0)
(2)
(3)
(1)
(2)
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
1
0
1
0
0
0
1
0
1
0
1
0
1
(2)
0
0
0
0
0
0
0
(2)
(1)
(1)
0
(1)
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Pre-Tax Income
(4)
N/A
(8)
-76%
(10)
-32%
(7)
+31%
(10)
-46%
(12)
-17%
(8)
+34%
(10)
-29%
(4)
+57%
1
N/A
(5)
N/A
(8)
-56%
(8)
+7%
(8)
-7%
(9)
-11%
3
N/A
1
-65%
(7)
N/A
(5)
+21%
(6)
-7%
(9)
-64%
(11)
-15%
(10)
+6%
(10)
+3%
(9)
+11%
(8)
+5%
(8)
-2%
(8)
+3%
(8)
-3%
(8)
+9%
(5)
+28%
(5)
+3%
(6)
-22%
(6)
+7%
(6)
-6%
(7)
-13%
(7)
+1%
(7)
-6%
(7)
+4%
(9)
-24%
(12)
-34%
(13)
-7%
(12)
+6%
(9)
+28%
Net Income
Tax Provision
0
0
(0)
(1)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Income from Continuing Operations
(4)
(8)
(10)
(8)
(10)
(12)
(8)
(10)
(4)
1
(5)
(8)
(8)
(8)
(9)
3
1
(7)
(5)
(6)
(9)
(11)
(10)
(10)
(9)
(8)
(8)
(8)
(8)
(8)
(5)
(5)
(6)
(6)
(6)
(7)
(7)
(7)
(7)
(9)
(12)
(13)
(12)
(9)
Income to Minority Interest
0
0
(0)
(0)
(0)
(0)
(0)
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Income (Common)
(4)
N/A
(8)
-82%
(11)
-41%
(8)
+28%
(10)
-35%
(12)
-12%
(8)
+33%
(10)
-28%
(4)
+57%
1
N/A
(5)
N/A
(8)
-56%
(8)
+8%
(8)
-7%
(9)
-11%
3
N/A
1
-64%
(7)
N/A
(5)
+21%
(6)
-7%
(9)
-64%
(11)
-15%
(10)
+5%
(10)
+3%
(9)
+11%
(8)
+5%
(8)
-2%
(8)
+3%
(8)
-3%
(8)
+9%
(5)
+28%
(5)
+3%
(6)
-22%
(6)
+7%
(6)
-6%
(7)
-13%
(7)
+1%
(7)
-6%
(7)
+5%
(9)
-22%
(12)
-35%
(13)
-8%
(12)
+5%
(10)
+19%
EPS (Diluted)
-0.01
N/A
-0.03
-200%
-0.04
-33%
-0.03
+25%
-0.03
N/A
-0.03
N/A
-0.02
+33%
-0.02
N/A
-0.01
+50%
0
N/A
-0.01
N/A
-0.02
-100%
-0.02
N/A
-0.02
N/A
-0.02
N/A
0.01
N/A
0
N/A
-0.02
N/A
-0.01
+50%
-0.01
N/A
-0.02
-100%
-0.02
N/A
-0.02
N/A
-0.02
N/A
-0.01
+50%
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
-0.08
N/A
0
N/A
-0.07
N/A
-0.09
-29%
-0.11
-22%
-0.11
N/A
-0.09
+18%
-0.06
+33%

See Also

Summary
GENE intrinsic value, competitors valuation, and company profile.
DCF Valuation
GENE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GENE stock valuation using valuation multiples.
Wall Street Estimates
GENE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GENE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 321,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett